Osteosarcoma, Chondrosarcoma, and Chordoma

Area of Science:

• Orthopedic Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Osteosarcoma, chondrosarcoma, and chordoma are rare bone cancers with significant management challenges.
• Their rarity and heterogeneity result in inadequate guidelines for diagnosis, treatment, and survivorship.
• Current standard care for localized osteosarcoma (OS) offers good prognosis in younger patients, but outcomes are poor for metastatic or recurrent disease and older patients.

Purpose of the Study:

• To review the current management challenges and therapeutic landscape for osteosarcoma, chondrosarcoma, and chordoma.
• To highlight the need for improved treatment strategies and specialized care for these rare bone tumors.
• To discuss the potential of new biologic insights for future therapeutic development.

Main Methods:

• Review of existing literature and clinical guidelines for osteosarcoma, chondrosarcoma, and chordoma.
• Analysis of current treatment standards, including chemotherapy, surgery, and radiotherapy.
• Discussion of prognostic factors and outcomes based on disease stage and patient age.

Main Results:

• Osteosarcoma shows high curability in localized disease for younger patients with standard neoadjuvant chemotherapy and surgery.
• Outcomes for unresectable, recurrent, or older adult osteosarcoma patients remain poor, indicating a need for novel therapies.
• Surgical resection is primary for chondrosarcoma and chordoma, with emerging biologic insights promising improved future treatments.

Conclusions:

• Despite advances, significant unmet needs persist for osteosarcoma, chondrosarcoma, and chordoma management.
• Multidisciplinary expert care in high-volume centers is crucial for optimizing outcomes in these rare bone tumors.
• Continued research into biologic insights is essential for developing more effective treatments for chondrosarcoma and chordoma.